Full-Time

Category Manager Direct Precision Materials

Johnson & Johnson

Johnson & Johnson

10,001+ employees

Global healthcare company offering pharma, devices.

Compensation Overview

$127.5k - $171k/yr

+ Bonus + Long-Term Incentive

Peabody, MA, USA

Hybrid

Hybrid role in Danvers, MA; willing to travel up to 30% internationally.

Bachelor's, Master's

Category
Operations & Logistics (1)

Get referred to Johnson & Johnson

See people who can refer or advise you

Requirements
  • A minimum of 5-8 years of strong procurement experience.
  • BSc in Operations/Supply Chain Management, Engineering or related field, MSc preferred
  • Good level of understanding of the Direct Precision Materials and industry landscape: Metals, ceramics, precision plastics, packaging materials and chemicals.
  • Broad-based understanding of business operations and practices and core procurement areas of focus (e.g., Spend Management, Category Management, Sourcing & Supplier Management).
  • Strong leadership, communication (verbal and written), influencing, collaboration skills.
  • Strong verbal and written communication skills with ability to confidently present complex information.
  • Experience to work across regions and understand markets.
  • Strong business sense.
  • Willingness to travel, particularly to visit suppliers. This position may require up to 30% International travel based on business needs.
Responsibilities
  • Develop and/or support the category sourcing strategy for the defined portfolio through Business needs assessment, Market intelligence, Supplier evaluations and sourcing choices.
  • Proactively engage business partners to identify needs and incorporate those needs into sub-category strategies.
  • Build supply network through developing, identifying suppliers applying deep subject matter expertise based on supply market analysis, industry intelligence.
  • Understand supply market trends, competitor analysis to deliver proactive sourcing strategies.
  • Lead or support sourcing initiatives to identify the right supplier partners, Influence decisions, delivering on-going value improvements while driving competitive advantage.
  • Develop spend analysis and gather market intelligence in alignment with business goals.
  • Develop and lead cost management initiatives; Prepare and execute RFQs for medium to high complexity sourcing decisions; Conduct negotiations with suppliers.
  • Build short term, and long-term capacities with suppliers to support business growth.
  • Deliver on financial, service, reliability, quality, innovation, and growth commitments.
  • Build and maintain relationships throughout Abiomed that results in dynamic interactive dialogue on a broad range of perspectives and information critical to the development of optimal approaches and solutions.
  • Drive sourcing activities for defined categories to support new products under development.
  • Develop and manage supplier partnerships to drive performance delivery, risk mitigation, and value through supplier enabled innovation.
  • Cultivate and use strategic relationships with key business partners (e.g., Internal partners, supplier leadership) to shape, optimize, and diversify the supply base.
  • Develop innovative and sustainable solutions to identify and mitigate risk, drive long-term, end-to-end value, and achieve unmet business needs. Identify and pursue opportunities to develop supplier capabilities.
  • Conduct Business Review meetings with suppliers that include holistic supplier performance management and review.
  • Systematically and efficiently manage contract creation, approval, administration, and compliance to maximize financial and operational performance while minimizing risk.
  • Represent procurement in End-to-End Supply Chain initiatives of the manufacturing network, capacity programs, digital tools/technology adoption, and resiliency.
  • Support the development and drive the Procurement vision for, with and through our stakeholder community.
  • Lead / Support projects in defined spend scope, to deliver procurement performance metrics.
Desired Qualifications
  • Experience in other related fields of Supply Chain, including External Operations, Manufacturing, Procurement, Distribution and / or related field is advantageous.
  • Medical Devices (specifically Abiomed relevant industry) experience preferred.
  • Multi-country and multi-sector experience preferred.
  • Continuous improvement/lean/six sigma experience, black belt preferred.
  • Experience with SAP preferred, or another ERP, device management and procurement systems.

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Carvykti topped $1 billion annual sales in January 2026, strengthening oncology.
  • IMAAVY won FDA approval on August 24, 2026, expanding a second launch.
  • Q2 2026 sales rose 6.6% to $25.31 billion, and guidance increased.

What critics are saying

  • The July 2026 talc settlement covers only existing claims, leaving future lawsuits open.
  • CVS dropped Stelara from main formularies in May 2026, accelerating biosimilar pressure.
  • Carvykti’s FDA boxed warning and Legend partnership constrain multiple myeloma expansion.

What makes Johnson & Johnson unique

  • J&J spans Innovative Medicine and MedTech, reducing dependence on any single franchise.
  • Carvykti and IMAAVY show J&J still converts R&D into first-in-class approvals.
  • Its oncology and immunology franchises offset Stelara’s erosion.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

-4%

1 year growth

-4%

2 year growth

-3%
Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.

Yahoo Finance
Aug 29th, 2026
AbbVie vs. Johnson & Johnson: Which healthcare stock offers better value in 2026?

AbbVie and Johnson & Johnson present distinct investment profiles in the healthcare sector. AbbVie focuses on biopharmaceuticals in immunology, oncology, and aesthetics, reporting fiscal 2025 revenue of $61.2 billion, up 8.7% year-over-year. Net income reached $4.3 billion with a 7% margin. The company generated $17.8 billion in free cash flow despite a negative debt-to-equity ratio of -21x. Johnson & Johnson operates through Innovative Medicine and MedTech segments. Revenue hit $94.2 billion in fiscal 2025, rising 6%. Net income nearly doubled to $26.8 billion from $14.1 billion the previous year, yielding a 29% margin. Its Darzalex portfolio accounted for 15% of total revenue. AbbVie relies heavily on three wholesale distributors for US sales, creating concentration risk. Johnson & Johnson maintains broader distribution globally.

Yahoo Finance
Aug 28th, 2026
JNJ stock surges 54% as TREMFYA's $2B quarter offsets STELARA's biosimilar decline

Johnson & Johnson's stock surged 54% between late August 2025 and late August 2026, outpacing the S&P 500's 20.5% return. The driver was a product transition that management flagged seven months before the rally began. STELARA faced biosimilar competition and declined 43.2% by mid-2025. Management named TREMFYA as its replacement, targeting the same inflammatory bowel disease patients who comprised 70% of STELARA's prescriptions. TREMFYA grew 30.1% during the same period. By July 2026, TREMFYA posted its first $2 billion quarter with 71% growth, offsetting STELARA's 55.7% decline. This product swap lifted the company's operational sales outlook to a $100.6 billion midpoint, demonstrating revenue durability despite losing a major franchise.